Close
  Indian J Med Microbiol
 

Figure 4: The targets of compound 1 (a), 2 (b), 7 (c), 10 (d) and 16 (e) in the complement activation cascade. 1-, 2-, 7-, 10-and 16-treated sera were mixed with multiple kinds of complement-depleted sera. The capacity to restore the hemolysis of depleted sera was estimated by adding 2% sheep red blood cells and anti-sheep erythrocyte antibody; “cont” represented the complement control group. The hemolysis significances of each complement-depleted sera were evaluated statistically before and after the addition of compound-treated normal human serum (***P < 0.001, **P < 0.01)

Figure 4: The targets of compound 1 (a), 2 (b), 7 (c), 10 (d) and 16 (e) in the complement activation cascade. 1-, 2-, 7-, 10-and 16-treated sera were mixed with multiple kinds of complement-depleted sera. The capacity to restore the hemolysis of depleted sera was estimated by adding 2% sheep red blood cells and anti-sheep erythrocyte antibody; “cont” represented the complement control group. The hemolysis significances of each complement-depleted sera were evaluated statistically before and after the addition of compound-treated normal human serum (***<i>P</i> < 0.001, **<i>P</i> < 0.01)